Keyphrases
Adverse Affects
9%
Adverse Events
9%
Anti-factor Xa
9%
Anticoagulation
9%
Anticoagulation Complications
9%
At Birth
9%
Care Institutions
9%
Critically Ill
9%
Critically Ill Neonates
9%
Enoxaparin
63%
Gestational Age
9%
Hospitalization
18%
Long-term Morbidity
9%
Low Molecular Weight Heparin
18%
Major Morbidity
9%
Medical Records
9%
Neonatal Intensive Care Unit
100%
Neonate
9%
Optimal Dosing
18%
Postmenstrual Age
18%
Premature Infant
9%
Relative Needs
9%
Relative Safety
9%
Retrospective Medical Record Review
9%
Short-term Morbidity
9%
Target Dose
9%
Tertiary Care
9%
Venous Thrombosis
100%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
9%
Blood Clotting Factor 10a
9%
Enoxaparin
63%
Low Molecular Weight Heparin
18%
Prematurity
18%
Retrospective Study
100%
Vein Thrombosis
100%